EMA/531238/2023

European Medicines Agency decision

P/0496/2023

of 1 December 2023

on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride) (EMEA-003174-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0496/2023

of 1 December 2023

on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride) (EMEA-003174-PIP01-21-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0546/2022 issued on 30 December 2022,

Having regard to the application submitted by Prilenia Therapeutics B.V. on 4 August 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 November 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pridopidine (hydrochloride), capsule, hard, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Prilenia Therapeutics B.V., 2-35 Gooimeer, 1411 DC - Naarden, Noord-Holland, The Netherlands.

EMA/PDCO/365472/2023
Amsterdam, 10 November 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-003174-PIP01-21-M01

Scope of the application

Active substance(s):

Pridopidine (hydrochloride)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Huntington disease

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Prilenia Therapeutics B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Prilenia Therapeutics B.V. submitted to the European Medicines Agency on 4 August 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0546/2022 issued on 30 December 2022.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 11 September 2023.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

Waiver

1.1. Condition:

Treatment of Huntington disease

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Huntington disease

2.1.1. Indication targeted by the PIP

Treatment of adolescent-onset juvenile Huntington disease (JHD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age appropriate oral formulation
Non-clinical studies	**Study 2 (NC23-TOX-22)** Definitive juvenile toxicity study in rats to evaluate the risks associated with use of pridopidine in paediatric patients with Huntington's disease (HD).
Clinical studies	**Study 3 (PL101-JHDPK201)** Double-blind, placebo controlled trial to evaluate pharmacokinetics, safety and efficacy of pridopidine in children from 2 years to less than 18 years of age with Huntington's disease.

Modelling and simulation studies	**Study 4** Modelling and simulation population pharmacokinetic (PK) study, to evaluate the use of the product in the treatment of juvenile Huntington's disease in children from 2 years to less than 18 years of age with Huntington's disease.
Other studies	Not applicable
Extrapolation plan	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By January 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.